Following a decline in pandemic-related demand, QIAGEN returned to growth but remained below its 2022 revenue level. The offer provides shareholders with a premium exit, while EQT takes on the task of expanding newer products and improving growth.

Build on repeat sales: Consumables and related revenue accounted for approximately 90% of FY2025 sales, supporting ongoing customer relationships and cash generation.

Expand newer platforms: Increase adoption of QIAstat-Dx and QIAcuity, broaden available tests and generate more supply sales from installed instruments.

Support long-term growth: Fund research, product launches and commercial expansion. Higher earnings and cash flow would help repay acquisition debt and support EQT’s returns.

Jonathan M. Pratt, CEO, QIAGEN: Said private ownership would allow QIAGEN to act faster and direct resources toward its most attractive long-term growth opportunities.

Roland Sackers, CFO, QIAGEN: Highlighted the shareholder premium and EQT’s resources as support for expanding QIAGEN’s capabilities and pursuing new opportunities.

Matteo Thun-Hohenstein, Partner, EQT: Pointed to QIAGEN’s established products, market positions and technical expertise, with EQT bringing industry experience and operational support for further growth.

QIAGEN N.V. is a Netherlands-based molecular diagnostics and life sciences company that develops instruments, testing kits, reagents and bioinformatics software for analyzing DNA, RNA and other biological materials. The company serves over 500,000 customers globally, including hospitals, clinical laboratories, pharmaceutical companies and research institutions.

QIAGEN operates across two primary markets including Molecular Diagnostics and Life Sciences.

1984–2000s | Research Foundation: Built laboratory relationships through DNA/RNA extraction kits and technical sales teams.

2007–2011 | Clinical Expansion: Acquired Digene and Cellestis, entering HPV and tuberculosis diagnostics.

2010s–2020 | Instrument Commercialization: Expanded QIAsymphony, QIAstat-Dx (2018) and QIAcuity (2020), using instrument placements and reagent-rental contracts to drive recurring consumable sales.

2019–2024 | Digital Sales Expansion: Expanded GeneGlobe for online product selection, ordering and customer engagement.

2025–2026 | Acquisitions and Partnerships: Acquired Parse Biosciences (2025), extending its reach to 3,000+ laboratories, and partnered with DiaSorin and Inpeco (2026) to integrate QuantiFERON into automated laboratory.

QIAGEN estimates its $12 billion addressable market will grow 4–6% annually through 2028. Traditional sample preparation is projected to grow 2–3%, compared with 8% for syndromic testing, over 10% for bioinformatics and over 15% for digital PCR. Growth is driven by laboratory automation, advanced diagnostics and increased testing volumes, while research spending remains sensitive to funding constraints. Roche's entry into tuberculosis testing adds competitive pressure. QIAGEN's growth depends on expanding its installed base, increasing instrument utilization and capturing share in higher-growth segments.

PE Interest: Blackstone and TPG’s Hologic acquisition, announced at up to $18.3 billion, shows interest in established diagnostics businesses. Repeat sales and steady cash flow help fund growth and repay debt.

VC Investment: Research tools led diagnostics-and-tools funding in H1 2026, while diagnostic analytics funding exceeded its full-year 2025 total. Most larger funding rounds were $30–90 million.

Tougher Funding for New Tests: Diagnostic-test funding was tracking approximately 40% lower in 2026, according to HSBC. Startups face greater pressure to prove demand and show how their tests will generate sales.

International Expansion: Thermo Fisher’s $3.1 billion acquisition of Sweden’s Olink shows how buyers can bring European research technology to more customers through their global sales networks.

Potential Synergy of Qiagen with Portfolio of EQT

SPT Labtech: Integrate QIAGEN's QIAseq and Parse Biosciences kits with SPT Labtech's automated liquid-handling systems to expand genomics workflows and increase consumable sales.

Europa Biosite: Leverage its network of 60,000+ researchers across 17 countries to distribute QIAGEN's PCR, NGS and single-cell products, expanding access to academic laboratories.

Parexel: Integrate QIAGEN's companion diagnostics, biomarker assays and genomic interpretation software into clinical trials, expanding pharmaceutical partnerships and test adoption.

Recipharm: Introduce QIAcuity digital PCR into Recipharm's cell and gene therapy manufacturing workflows for quality control, increasing instrument placements and reagent demand. • Mabtech: Combine complementary immunology and molecular testing capabilities for vaccine, oncology and infectious disease research, creating potential cross-selling opportunities.